

Global Automated and Closed Cell Therapy Market

Market Research Report | 2024-08-06 | 112 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

The report highlights the current and future market potential of automated and closed cell therapy systems and a detailed analysis of the market drivers, restraints, and opportunities. The report also covers market projections for 2029, a competitive environment, patent, and product analysis. The report provides market estimates and forecasts for automated and closed cell therapy based on automation, cell type, application, and region. The market is segmented into CAR-T cells, stem cells, and other cell types based on cell type. The market is categorized as clinical and commercial based on the application type. The market is segmented into semi-automated and fully automated based on the type of automation. The semi-automated systems are further segmented based on workflow into apheresis, expansion, fill-finish, separation, and others. The report includes company profiles of the key industry players with detailed information about their business segments, financials, product portfolios, and recent developments. The report does not cover automated systems for basic operations such as pipetting or mixing.

By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America-the U.S., Canada, and Mexico; Europe-Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific-China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecast through 2029.

Report Includes:

- 43 data tables and 46 additional tables
- An overview of the current and future global markets for automated and closed cell therapy

Scotts International, EU Vat number: PL 6772247784

- Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024 and projected CAGRs through 2029
- Estimates of the market size and revenue forecasts, with market share analysis based on the automation type, cell type, application, and region
- Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
- Overview of the sustainability and ESG trends, with emphasis on the ESG practices followed by leading companies, their ESG rankings and consumer attitudes
- Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding.
- Profiles of the leading companies, including Danaher Corp., Thermo Fischer Scientific Inc., Lonza, and Sartorius AG

Executive Summary

Summary:

In 2023, the global market for automated and closed cell therapy was valued at \$1.5 billion. The market is forecast to grow at a CAGR of 23.9% to reach \$5.3 billion at the end of 2029.

The increasing demand for regenerative medicine and the growing need for decentralized manufacturing of CAR-T therapies drive the market's growth. The high cost, integration challenges and regulatory uncertainties challenge the market's growth.

This report sections the global market by automation type, cell type, application, and region. By automation type, the market is categorized into semi-automated and fully automated. The semi_automated and closed cell therapy segment, which held the largest share in 2023, is expected to grow at a CAGR of 22.2% during the forecast period. The semi-automated and closed cell therapy segment is further categorized into apheresis, expansion, fill-finish, separation, and others based on workflow.

In terms of application, the clinical segment is forecast to grow at a CAGR of 22.3% during the forecast period. This segment accounted for 82.8% of the market in 2023, reaching a value of \$4.1 billion through 2029.

The CAR-T cell therapy segment accounted for 39.5% of the market by cell type in 2023. This segment is expected to grow at a CAGR of 23.8% during the forecast period, reaching a value of \$2.1 billion at the end of 2029.

North America held the largest market share of 41.8% by region in 2023. Increasing R&D activities and the growing number of regional service providers are responsible for the high share.

Leading companies in the global market include Danaher Corp, Thermo Fisher Scientific Inc., Lonza, Sartorius AG, and Terumo Corp.

Table of Contents:

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Insights
Chapter 2 Market Overview
Overview
Types of Cell Therapy
Applications of Cell Therapy

Scotts International, EU Vat number: PL 6772247784

Regenerative Medicine

Cancer

Autoimmune Disorders

Chapter 3 Market Dynamics

Market Dynamics Snapshot

Market Drivers

Point-of-Care Manufacturing in CAR-T Therapies

Growing Demand for Regenerative Medicine

Market Restraints

High Costs and Integration Challenges

Regulatory Uncertainties

Market Opportunities

Increasing Startups in Cell Therapy Manufacturing

Scalable Platforms

Chapter 4 Emerging Technologies and Developments

Introduction

Real-Time Monitoring (RTM) of Operations

Off-the-Shelf Cell Therapies

Miniaturization of Cell Therapy Systems

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown

Global Automated and Closed Cell Therapy Market by Automation Type

Semi-Automated Cell Therapy

Fully Automated Cell Therapy

Global Automated and Closed Cell Therapy Market by Cell Type

CAR-T Cells

Stem Cells

Other Cell Types

Global Automated and Closed Cell Therapy Market by Application

Market Size and Forecast

Clinical

Commercial

Geographic Breakdown

Global Market for Automated and Closed Cell Therapy by Region

Market Size and Forecast

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Chapter 6 Competitive Intelligence

Competitive Landscape

Partnerships

Investments and Funding

Patent Analysis

Chapter 7 Sustainability in the Automated and Closed Cell Therapy Market

Introduction

Sustainability in the Automated and Closed Cell Therapy Industry

Scotts International. EU Vat number: PL 6772247784

Understanding the ESG Data Environmental Performance Social Performance Governance Performance Concluding Remarks from BCC

Chapter 8 Appendix

Methodology

Sources

Acronyms

Company Profiles

ADVA BIOTECHNOLOGY

BIOSPHERIX LTD.

CELLARES

DANAHER CORP.

FRESENIUS SE & CO. KGAA

LONZA

MILTENYI BIOTEC

SARTORIUS AG

TERUMO CORP.

THERMO FISHER SCIENTIFIC INC.



Global Automated and Closed Cell Therapy Market

Market Research Report | 2024-08-06 | 112 pages | BCC Research

To place an Order wit	h Scotts International:			
Print this form				
Complete the re	levant blank fields and sign			
Send as a scann	ed email to support@scotts-interna	tional.com		
ORDER FORM:				
Select license	License			Price
	Single User License			\$5500.00
	2-5 Users License			\$6600.00
	Site License			\$7920.00
	Enterprise License			\$9504.00
			VAT	
			Total	
*Please circle the releva	nt license option. For any questions plea	ase contact support@	Scotts-international com or 0048 603 3	94 346
	: 23% for Polish based companies, indivi			
	, , , , , , , , , , , , , , , , , , , ,			
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID / NIP number*		
Address*		City*		
Zip Code*		Country*		
		Date	2025-06-25	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

Scotts International. EU Vat number: PL 6772247784